Skylar J Ferrara1, J Matthew Meinig1, Andrew T Placzek1, Tapasree Banerji1, Peter McTigue1, Meredith D Hartley1, Hannah S Sanford-Crane1, Tania Banerji1, Dennis Bourdette2, Thomas S Scanlan3. 1. Program in Chemical Biology, Department of Physiology & Pharmacology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, United States. 2. Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, United States. 3. Program in Chemical Biology, Department of Physiology & Pharmacology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, United States. Electronic address: scanlant@ohsu.edu.
Abstract
Current therapeutic options for treating demyelinating disorders such as multiple sclerosis (MS) do not stimulate myelin repair, thus creating a clinical need for therapeutic agents that address axonal remyelination. Thyroid hormone is known to play an important role in promoting developmental myelination and repair, and CNS permeable thyromimetic agents could offer an increased therapeutic index compared to endogenous thyroid hormone. Sobetirome is a clinical stage thyromimetic that has been shown to have promising activity in preclinical models related to MS and X-linked adrenoleukodystrophy (X-ALD), a genetic disease that involves demyelination. Here we report a new series of sobetirome prodrugs containing ethanolamine-based promoieties that were found to undergo an intramolecular O,N acyl migration to form the pharmacologically relevant amide species. Several of these systemically administered prodrugs deliver more sobetirome to the brain compared to unmodified sobetirome. Pharmacokinetic properties of the parent drug sobetirome and amidoalcohol prodrug 3 are described and prodrug 3 was found to be more potent than sobetirome in target engagement in the brain from systemic dosing.
Current therapeutic options for treating demyelinating disorders such as n class="Disease">multiple sclerosis (MS) do not stimulate myelin repair, thus creating a clinical need for therapeutic agents that address axonal remyelination. Thyroid hormone is known to play an important role in promoting developmental myelination and repair, and CNS permeable thyromimetic agents could offer an increased therapeutic index compared to endogenous thyroid hormone. Sobetirome is a clinical stage thyromimetic that has been shown to have promising activity in preclinical models related to MS and X-linked adrenoleukodystrophy (X-ALD), a genetic disease that involves demyelination. Here we report a new series of sobetirome prodrugs containing ethanolamine-based promoieties that were found to undergo an intramolecular O,N acyl migration to form the pharmacologically relevant amide species. Several of these systemically administered prodrugs deliver more sobetirome to the brain compared to unmodified sobetirome. Pharmacokinetic properties of the parent drug sobetirome and amidoalcohol prodrug 3 are described and prodrug 3 was found to be more potent than sobetirome in target engagement in the brain from systemic dosing.
Authors: Emily G Baxi; Jason T Schott; Amanda N Fairchild; Leslie A Kirby; Rabia Karani; Prech Uapinyoying; Carlos Pardo-Villamizar; Jeffrey R Rothstein; Dwight E Bergles; Peter A Calabresi Journal: Glia Date: 2014-05-24 Impact factor: 7.452
Authors: S U Trost; E Swanson; B Gloss; D B Wang-Iverson; H Zhang; T Volodarsky; G J Grover; J D Baxter; G Chiellini; T S Scanlan; W H Dillmann Journal: Endocrinology Date: 2000-09 Impact factor: 4.736
Authors: Soledad Bárez-López; Meredith D Hartley; Carmen Grijota-Martínez; Thomas S Scanlan; Ana Guadaño-Ferraz Journal: Thyroid Date: 2018-06-29 Impact factor: 6.568
Authors: Meredith D Hartley; Mitra D Shokat; Margaret J DeBell; Tania Banerji; Lisa L Kirkemo; Thomas S Scanlan Journal: Cell Chem Biol Date: 2020-03-12 Impact factor: 8.116
Authors: Meredith D Hartley; Tania Banerji; Ian J Tagge; Lisa L Kirkemo; Priya Chaudhary; Evan Calkins; Danielle Galipeau; Mitra D Shokat; Margaret J DeBell; Shelby Van Leuven; Hannah Miller; Gail Marracci; Edvinas Pocius; Tapasree Banerji; Skylar J Ferrara; J Matthew Meinig; Ben Emery; Dennis Bourdette; Thomas S Scanlan Journal: JCI Insight Date: 2019-04-18
Authors: P Chaudhary; G H Marracci; E Calkins; E Pocius; A L Bensen; T S Scanlan; B Emery; D N Bourdette Journal: J Neuroimmunol Date: 2020-12-27 Impact factor: 3.478